Search | IOVS | ARVO Journals

View

Showing 1 – 12 of 12

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2022

Age-stratified quantitative ultrasound biomicroscopy image analysis of iris thickness using multivariable analysis to optimize reliability

Trisha Miglani; Michael Chang; Taylor Kolosky; Moran Roni Levin; Camilo Martinez; Marlet Bazemore; Mohamad Jaafar; William Madigan; Janet Alexander

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):4406 – F0085. doi:

ARVO Annual Meeting Abstract June 2022

Identification of pericyte biomarkers in aqueous and vitreous humor reflecting diabetic retinopathy severity

Stephanie Hartouni; Irene Tom; Daphne Yang; Ricardo Lamy; Joshua Wu; Jay M. Stewart; Michael Chang

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):3618 – A0073. doi:

ARVO Annual Meeting Abstract June 2022

Aqueous humor vascular endothelial growth factor pharmacodynamics in the phase 3 Archway trial of the Port Delivery System with ranibizumab

Murtaza Adam; Laura Barras; Mauricio Maia; Shamika Gune; Katie Maass; Michael Chang

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):4285. doi:

ARVO Annual Meeting Abstract June 2021

Ultrasound biomicroscopy image analysis technique for the human iris

Trisha Miglani; Michael Chang; Moran Roni Levin; Janet Leath Alexander

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):387. doi:

ARVO Annual Meeting Abstract June 2020

Lampalizumab inhibits ocular alternative complement activity in patients with geographic atrophy secondary to age-related macular degeneration

Michael Chang; Verena Steffen; Lee Honigberg; Rose Edmonds

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):2992. doi:

ARVO Annual Meeting Abstract June 2020

Identification of DKK3 as an Ocular Pharmacodynamic Biomarker for anti-HtrA1 in a Phase 1 study for Geographic Atrophy Secondary to Age-related macular degeneration

Irene Tom; Victoria Pham; Kenneth J Katschke; Wei Li; Wei-Ching Liang; Johnny Guiterrez; Andrew Ah Young; Shadi Eshghi; Michael Chang; Phillip Lai; Menno van Lookeren Campagne; Daniel Kirchhofer; Amos Baruch; Jennie Lill; Lee Honigberg

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):4306. doi:

ARVO Annual Meeting Abstract July 2019

Prophylactic Intravitreal Bevacizumab after Plaque Radiotherapy for Uveal Melanoma: Analysis of 1311 Eyes of 1310 Patients by Age

Michael Chang; Lauren A Dalvin; Li-Anne S Lim; Mehdi Mazloumi; Antonio Yaghy; Arman Mashayekhi; Carol L. Shields

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):721. doi:

ARVO Annual Meeting Abstract July 2019

Intravitreal melphalan for vitreoretinal lymphoma

Li-Anne S Lim; Lauren A Dalvin; David Ancona-Lezama; Michael Chang; Arman Mashayekhi; Carol L. Shields

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):2778. doi:

ARVO Annual Meeting Abstract July 2019

Survival Times in Patients with Vitreoretinal Lymphoma. Analysis of 95 Patients at a Single Ocular Oncology Center.

Lauren A Dalvin; Li-Anne S Lim; David Ancona-Lezama; Mehdi Mazloumi; Michael Chang; Arman Mashayekhi; Carol L. Shields

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):3543. doi:

ARVO Annual Meeting Abstract July 2018

The initial growth rate of geographic atrophy lesions appears to strongly predict future growth rate

Simon S. Gao; Michel Friesenhahn; Michael Chang; Alexandre Coimbra; Alex de Crespigny; Justin Elstrott; Jason Gow; Phillip Lai; Eric C Strauss

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):3241. doi:

ARVO Annual Meeting Abstract September 2016

Treatment of Refractory Inflammatory Cystoid Macular Edema with Pegylated Interferon Alfa-2A: A Retrospective Chart Review

Hillary Stiefel; Laura J Kopplin; Thomas Arno Albini; Srav Vegunta; Michael Chang; Eric B Suhler

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):1872. doi:

ARVO Annual Meeting Abstract April 2014

Duration of Immunomodulator Therapy and Uveitic Relapse

David Mostafavi; Michael Chang; Vicente Diaz; John Mauro; Sanjay Kedhar; Michael Samson

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):2516. doi:

Advertisement